In the early 1980s, biotechnology caused worldwide excitement as a high technology with almost unlimited potential in science, medicine, and industry. It not only allowed the manufacture of traditional products more quickly and inexpensively, but also offered the possibility of synthesizing valuable materials anew. All this made it very attractive to Japanese policymakers, who ‘targeted’ it as a high priority area for economic growth. Originally published in 1989, Biotechnology in Japan is the first published in English to analyse the Japanese effort to promote the new biotechnology industries. The author examines the strategies used for developing biotechnology in Japan and looks at the active role of government in a field in which the Japanese rapidly became the world leaders. Focusing on the making and implementation of biotechnology policy, he considers the relationship between the public and the private sector, and makes use of different political constructs to analyse Japan’s complex and unique balance between competitive market forces and collective interest.

Biotechnology in Japan is a complete guide to economic, scientific and regulatory aspects of Japanese research centres and companies. Profiles for more than 400 private Japanese companies and almost 200 universities and research institutes are given in great detail. Ministries providing research guidelines and ongoing research projects are analysed. The book is the first comprehensive source in the English language and is of particular interest to consultants, managers and researchers seeking cooperation with Japanese partners.

Americans praise medical technology for saving lives and improving health. Yet, new technology is often cited as a key factor in skyrocketing medical costs. This volume, second in the Medical Innovation at the Crossroads series, examines how economic incentives for innovation are changing and what that means for the future of health care. Up-to-date with a wide variety of examples and case studies, this book explores how payment, patent, and regulatory policiesâ€"as well as the involvement of numerous government agenciesâ€"affect the introduction and use of new pharmaceuticals, medical devices, and surgical procedures. The volume also includes detailed comparisons of policies and patterns of technological innovation in Western Europe and Japan. This fact-filled and practical book will be of interest to economists, policymakers, health administrators, health care practitioners, and the concerned public.

A complete bibliography on the issues of commercialization & economics in biotechnology. Includes: cost benefit analysis, market research, forecasting, economic impact, market trends, etc. Each of the 209 entries includes: title, author, language. An abstract is included for some books. Subject & author indices.

This book covers the biotechnology of all the major fruit and nut species. Since the very successful first edition of this book in 2004, there has been rapid progress for many fruit and nut species in cell culture, genomics and genetic transformation, especially for citrus and papaya. This book covers both these cutting-edge technologies and regeneration pathways, protoplast culture, in vitro mutagenesis, ploidy manipulation techniques that have been applied to a wider range of species. Three crop species, Diospyros kaki (persimmon), Punica granatum (pomegranate) and Eriobotrya japonica (loquat) are included for the first time. The chapters are organized by plant family to make it easier to make comparisons and exploitation of work with related species. Each chapter discusses the plant family and the related wild species for 38 crop species, and has colour illustrations. It is essential for scientists and post graduate students who are engaged in the improvement of fruit, nut and plantation crops.

The Business of Biotechnology: From the Bench to the Street thoroughly examines the existing and future business challenges for biotechnology, providing a unique insight into the intricate web of critical factors with which biotechnology entrepreneurs must come to terms if they wish to be successful. The book begins with discussions of the evolution of biotechnology; entrepreneurship in the biotechnology industry; university-industry technology transfer process; and the life cycle of a biotechnology company. It considers the prospects for biotechnology, from the perspective of a venture capitalist and human resource practitioner. There are separate chapters that deal with the cloning and expression of recombinant gene products; developing strategies to reduce the cost-to-produce (CTP) therapeutic proteins; intellectual property protection; and the regulation of commercial biotechnology. The final chapters cover the marketing of biotechnology companies and products; the performance of biotechnology stocks; mergers and acquisitions in the biotechnology industry, and prospects for the Japanese and European biotechnology industry.